Wilson Sonsini Goodrich & Rosati has advised Oak Hill Bio on IP matters. Cooley has advised Research Alliance Corporation III (RACC). OHB Pediatrics Ltd., operating as...
Oak Hill Bio and RACC Announce $175 Million Business Combination to Form Nasdaq-Listed Rare Disease Company
UCB to Acquire Candid Therapeutics in $2.2 Billion Deal
Cooley and Wilson Sonsini Goodrich & Rosati have advised Candid Therapeutics. Covington & Burling has represented UCB. UCB, a global biopharmaceutical company, has announced a definitive...
Angion’s Merger Agreement with Elicio Therapeutics
Cooley advised Angion on the deal. Angion, a clinical-stage biopharmaceutical company, announced its definitive merger agreement with Elicio Therapeutics. Elicio will merge with a wholly owned subsidiary...
AstraZeneca’s Acquisition of CinCor Pharma
Covington & Burling advised AstraZeneca. Skadden represented Centerview Partners LLC, the exclusive financial advisor to CinCor Pharma Inc. Cooley advised CinCor Pharma. CinCor Pharma Inc. (“CinCor”)...
Kite’s Acquisition of Tmunity
Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company. The acquisition will provide...
Amgen’s Acquisition of Horizon Therapeutics
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
AstraZeneca’s Acquisition of Neogene Therapeutics
Cooley advised Neogene Therapeutics on the deal. Neogene Therapeutics, a global clinical-stage biotechnology company, signed its definitive agreement to be acquired by AstraZeneca for a total consideration...
Vertex’s $320 Million Acquisition of ViaCyte
Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
Bristol Myers Squibb’s $4.1 Billion Acquisition of Turning Point Therapeutics
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
Great Hill Partners’ Investment in Prodege
Cooley LLP advised Prodege on the deal. Prodege, a cutting-edge marketing and consumer insights platform, announced its definitive agreement to secure a major investment from private equity...